Author(s):
LK Kanthal, P Mondal, Vaswani, B Mahanti.
Email(s):
lkkhaldia@gmail.com
DOI:
Not Available
Address:
LK Kanthal1*, P Mondal1, Vaswani L2 and B Mahanti1
1Bharat Technology, Banitabla, Howrah, W.B, India.
2Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, India.
*Corresponding Author
Published In:
Volume - 2,
Issue - 3,
Year - 2010
ABSTRACT:
Diabetes is a condition primarily defined by the level of hyperglycaemia giving rise to risk of macro and micro vascular complication and diminished quality of life. Roman physician Areataeus was introduced the name diabetes in 1st century A.D. Diabetes treatment include a number of drugs either can be used alone or in combination. The present articles concentrate on the phase -3 studies of Welchol as an adjunct to Metformin in type –ll diabetes who are not responding to other combination of anti-diabetic drugs.
Cite this article:
LK Kanthal, P Mondal, Vaswani , B Mahanti. Phase-3 Studies of Welchol on Anti-diabetic Activity. Research J. Pharmacology and Pharmacodynamics. 2010; 2(3): 211-214.
Cite(Electronic):
LK Kanthal, P Mondal, Vaswani , B Mahanti. Phase-3 Studies of Welchol on Anti-diabetic Activity. Research J. Pharmacology and Pharmacodynamics. 2010; 2(3): 211-214. Available on: https://rjppd.org/AbstractView.aspx?PID=2010-2-3-12